HealthDay: Immunotherapy drug did not increase adverse surgery events
A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery.
HealthDay featured the research, recently published in JAMA Otolaryngology - Head & Neck Surgery, that evaluated outcomes during and after surgery when patients with head and neck cancer were given the immunotherapy drug pembrolizumab prior to surgery.
"What we found was that patients who received preoperative treatment with immunotherapy did not have an increase in morbidities around the time of surgery,” said Alice Tang, MD, first author on the study, assistant professor of clinical otolaryngology in UC’s College of Medicine, a UC Health physician and a University of Cincinnati Cancer Center member.
Featured photo at top of Alice Tang, MD, center, with patient. Photo provided by UC Health.
Related Stories
Protecting the brain with chemistry
April 24, 2026
UC chemistry student Carter St. Clair will pursue his interest in computational chemistry through a new fellowship at the Air Force Research Laboratory. His topic: new applications in AI in human health.
A family tradition continues at UC College of Nursing
April 24, 2026
When Ashley Enginger walks across the stage at this spring’s commencement ceremony, she will leave behind a UC College of Nursing that her family is far from finished with. Her sister Sarah is already two years in, and their youngest sister Lauren is set to arrive in the fall.
UC works with local paramedics to advance sudden cardiac arrest research
April 24, 2026
A University of Cincinnati study demonstrates the feasibility of emergency medicine researchers partnering with community emergency medical services nationwide to investigate the causes of sudden cardiac arrest.